327 related articles for article (PubMed ID: 30975981)
41. Angelica gigas Nakai and Decursin Downregulate Myc Expression to Promote Cell Death in B-cell Lymphoma.
Kim E; Nam J; Chang W; Zulfugarov IS; Okhlopkova ZM; Olennikov D; Chirikova NK; Kim SW
Sci Rep; 2018 Jul; 8(1):10590. PubMed ID: 30002430
[TBL] [Abstract][Full Text] [Related]
42. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase.
Shreeram S; Hee WK; Demidov ON; Kek C; Yamaguchi H; Fornace AJ; Anderson CW; Appella E; Bulavin DV
J Exp Med; 2006 Dec; 203(13):2793-9. PubMed ID: 17158963
[TBL] [Abstract][Full Text] [Related]
43. FoxO3 suppresses Myc-driven lymphomagenesis.
Vandenberg CJ; Motoyama N; Cory S
Cell Death Dis; 2016 Jan; 6(1):e2046. PubMed ID: 26764572
[TBL] [Abstract][Full Text] [Related]
44. Transcriptional Activation of MYC-Induced Genes by GCN5 Promotes B-cell Lymphomagenesis.
Farria AT; Plummer JB; Salinger AP; Shen J; Lin K; Lu Y; McBride KM; Koutelou E; Dent SYR
Cancer Res; 2020 Dec; 80(24):5543-5553. PubMed ID: 33168647
[TBL] [Abstract][Full Text] [Related]
45. Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway.
Ta VB; de Bruijn MJ; ter Brugge PJ; van Hamburg JP; Diepstraten HJ; van Loo PF; Kersseboom R; Hendriks RW
Blood; 2010 Feb; 115(7):1385-93. PubMed ID: 20008789
[TBL] [Abstract][Full Text] [Related]
46. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
47. Differential effects of Vav-promoter-driven overexpression of BCLX and BFL1 on lymphocyte survival and B cell lymphomagenesis.
Tuzlak S; Haschka MD; Mokina AM; Rülicke T; Cory S; Labi V; Villunger A
FEBS J; 2018 Apr; 285(8):1403-1418. PubMed ID: 29498802
[TBL] [Abstract][Full Text] [Related]
48. Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained.
Vandenberg CJ; Waring P; Strasser A; Cory S
Blood; 2014 Aug; 124(7):1099-109. PubMed ID: 24986687
[TBL] [Abstract][Full Text] [Related]
49. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.
Campbell KJ; Bath ML; Turner ML; Vandenberg CJ; Bouillet P; Metcalf D; Scott CL; Cory S
Blood; 2010 Oct; 116(17):3197-207. PubMed ID: 20631380
[TBL] [Abstract][Full Text] [Related]
50. CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis.
Lu Y; Wu Y; Feng X; Shen R; Wang JH; Fallahi M; Li W; Yang C; Hankey W; Zhao W; Ganju RK; Li MO; Cleveland JL; Zou X
J Clin Invest; 2014 Apr; 124(4):1672-84. PubMed ID: 24614102
[TBL] [Abstract][Full Text] [Related]
51. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells.
Wang P; Lushnikova T; Odvody J; Greiner TC; Jones SN; Eischen CM
Oncogene; 2008 Mar; 27(11):1590-8. PubMed ID: 17828300
[TBL] [Abstract][Full Text] [Related]
52. Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.
Lefebure M; Tothill RW; Kruse E; Hawkins ED; Shortt J; Matthews GM; Gregory GP; Martin BP; Kelly MJ; Todorovski I; Doyle MA; Lupat R; Li J; Schroeder J; Wall M; Craig S; Poortinga G; Cameron D; Bywater M; Kats L; Gearhart MD; Bardwell VJ; Dickins RA; Hannan RD; Papenfuss AT; Johnstone RW
Nat Commun; 2017 Mar; 8():14581. PubMed ID: 28262675
[TBL] [Abstract][Full Text] [Related]
53. The Transcription Factor ASCIZ and Its Target DYNLL1 Are Essential for the Development and Expansion of MYC-Driven B Cell Lymphoma.
Wong DM; Li L; Jurado S; King A; Bamford R; Wall M; Walia MK; Kelly GL; Walkley CR; Tarlinton DM; Strasser A; Heierhorst J
Cell Rep; 2016 Feb; 14(6):1488-1499. PubMed ID: 26832406
[TBL] [Abstract][Full Text] [Related]
54. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
55. Inactivation of p53 is insufficient to allow B cells and B-cell lymphomas to survive without Dicer.
Adams CM; Eischen CM
Cancer Res; 2014 Jul; 74(14):3923-34. PubMed ID: 24840646
[TBL] [Abstract][Full Text] [Related]
56. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
[TBL] [Abstract][Full Text] [Related]
57. The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis.
Cardone M; Kandilci A; Carella C; Nilsson JA; Brennan JA; Sirma S; Ozbek U; Boyd K; Cleveland JL; Grosveld GC
Mol Cell Biol; 2005 Mar; 25(6):2395-405. PubMed ID: 15743832
[TBL] [Abstract][Full Text] [Related]
58. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
[TBL] [Abstract][Full Text] [Related]
59. Reduction of Prep1 levels affects differentiation of normal and malignant B cells and accelerates Myc driven lymphomagenesis.
Iotti G; Mejetta S; Modica L; Penkov D; Ponzoni M; Blasi F
PLoS One; 2012; 7(10):e48353. PubMed ID: 23133585
[TBL] [Abstract][Full Text] [Related]
60. Enhanced pro-apoptotic activity of rituximab through IBTK silencing in non-Hodgkin lymphoma B-cells.
Vecchio E; Marino R; Mimmi S; Canale C; Caiazza C; Arcucci A; Ruocco MR; Schiavone M; Santamaria G; Palmieri C; Iaccino E; Mallardo M; Quinto I; Fiume G
Front Oncol; 2024; 14():1339584. PubMed ID: 38371626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
